Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5524734 | 0.79 | SNCA (0.40) | KMT2ASNCALMNASLC6A2SLC6A4 | |
| SCHEMBL2416029 | 0.78 | SNCA (0.42) | KMT2AMEN1SNCAALDH1A1ALOX15 | |
| SCHEMBL2410011 | 0.78 | SNCA (0.34) | SNCA | |
| SCHEMBL1437613 | 0.78 | EGFR (0.55) | EGFR | |
| SCHEMBL12642458 | 0.77 | TP53 (0.37) | SNCA | |
| SCHEMBL2659673 | 0.77 | AR (0.40) | SNCAPGRARCYP11B2 | |
| SCHEMBL5892466 | 0.77 | MEN1 (0.38) | EGFRKMT2AMEN1SNCAPGR | |
| SCHEMBL4264297 | 0.76 | SNCA (0.44) | SNCA | |
| SCHEMBL18548331 | 0.76 | SNCA (0.35) | SNCA | |
| SCHEMBL16626289 | 0.76 | SNCA (0.39) | SNCAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037905-B2 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2006-05-02 | — | — | US | claimed |
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | US | claimed |
| WO-2003105860-A1 | PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | claimed |
| US-7037905-B2 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2006-05-02 | — | — | US | disclosed |
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | NOVO NORDISK A/S (DK) | 2004-03-18 | — | — | US | disclosed |
| WO-2003105860-A1 | PHARMACEUTICAL USE OF BORONIC ACIDS AND ESTERS THEREOF | NOVO NORDISK A/S (DK) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053889-A1 | Pharmaceutical use of boronic acids and esters thereof | LIPE, CEL, LIPA | EGFR 1647/4885KMT2A 3233/4885MEN1 526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.